Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,852 GBX | +0.11% |
|
+1.93% | +3.52% |
24/06 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
20/06 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.52% | 5.32B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Transcript : Hikma Pharmaceuticals PLC Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-12-2021 05